Can our bodies be trained to destroy cancer cells? CAR-T therapies have undoubtedly garnered significant attention and investment over the past several years even with the risks and development challenges that scientists continue to face. In the BioHealth Capital Region, gene therapy companies are rapidly emerging making the District of Columbia and its’ surrounding area a new hub for gene therapy. Through external partnership, Janssen R&D is jointly working to develop solutions in the gene therapy and CAR-T space.

Click here to learn more.